Fred Hutchinson Cancer Center

319 total trials 224 currently recruiting 75 completed

Trial Pipeline

RECRUITING Phase 1

Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma

NCT07181941

RECRUITING NA

Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians

NCT07282158

RECRUITING NA

Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial

NCT06802172

RECRUITING Phase 2

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

NCT07228624

RECRUITING NA

Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell Lung Cancer, BOOST Trial

NCT06983899

RECRUITING Phase 2

Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance

NCT07209371

RECRUITING Phase 1

Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial

NCT07227571

RECRUITING Phase 1

ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

NCT07098364

RECRUITING Phase 2

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

NCT06817889

RECRUITING NA

Improving Uptake of Surveillance in Colorectal Cancer Survivors Through Navigation and Web Education

NCT06995924

RECRUITING NA

Patient Navigation and the Planning Advance Care Together Website to Improve Goals of Care Conversations in Hematopoietic Cell Transplant Survivors, IMPACT-HCT Trial

NCT07052630

RECRUITING Phase 2

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

NCT07046078

RECRUITING Phase 2

Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia

NCT06752694

RECRUITING Phase 1

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

NCT06928662

RECRUITING Phase 2

Axatilimab for Sclerotic Chronic Graft-versus-Host Disease

NCT07011810

RECRUITING NA

A Checklist (Advanced Care Planning) for The Assessment of Mobility Needs in Patients With Sarcoma

NCT05835154

RECRUITING NA

Evaluating the Effects of an Exercise Intervention on the Gut Microbiota in Stage II-III Colorectal Cancer Survivors

NCT05930496

RECRUITING NA

A Digital Smoking Cessation Intervention for Helping American Indians and Alaska Natives Quit Smoking, IndigeQuit Trial

NCT06145763

RECRUITING Phase 2

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

NCT06839053

RECRUITING NA

Remotely Delivered, Community-Aligned Weight Loss Interventions Among Breast Cancer Survivors, ¡Vida! Trial

NCT05930483

RECRUITING

Development of Measures to Screen for Financial Hardship in Alzheimer's Disease and Dementia

NCT06922188

RECRUITING Phase 1

FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT06609928

RECRUITING NA

Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning

NCT04515810

RECRUITING Phase 1

Fecal Microbiota Transplant and Dietary Fiber Supplementation for the Treatment of Gut Graft Versus Host Disease

NCT05067595

RECRUITING Phase 1

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

NCT06236139

RECRUITING NA

Cooking for Your Health in Southern New Mexico: an 8-week, Bilingual (English and Spanish) Nutritional Intervention in Adults Living in Doña Ana and Otero Counties

NCT06609057

RECRUITING Phase 2

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

NCT06145633

RECRUITING Phase 2

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

NCT06013423

RECRUITING Phase 2

IVIG for Infection Prevention After CAR-T-Cell Therapy

NCT05952804

RECRUITING Phase 1

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

NCT06034470

RECRUITING Phase 1

Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations

NCT06043713

RECRUITING Phase 2

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

NCT05996627

RECRUITING Phase 2

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

NCT04941716

RECRUITING NA

Sustained Oral Fiber Supplementation for Patients Undergoing Donor Stem Cell Transplantation for Hematological Malignancies

NCT04829136

RECRUITING Phase 1

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

NCT05098210

RECRUITING

The Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation (The RV-BOS Study)

NCT05250037

RECRUITING Phase 2

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders

NCT03980769

RECRUITING Phase 2

Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

NCT04370301

RECRUITING Phase 2

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

NCT04195633

RECRUITING Phase 1

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

NCT04375631

RECRUITING

Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study

NCT04431479

RECRUITING Phase 1

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

NCT04083183

RECRUITING Phase 2

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

NCT03970096

RECRUITING Phase 2

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

NCT03779854

RECRUITING Phase 1

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

NCT03670966

RECRUITING Phase 1

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

NCT03326921

RECRUITING Phase 1

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

NCT03128034

ACTIVE NOT RECRUITING NA

Mindfulness Intervention for Improving Nutrition in the Digital Kitchen Among Stage I-III Breast Cancer Survivors, MIND Trial

NCT06643455

ACTIVE NOT RECRUITING Phase 2

Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation

NCT06026371

ACTIVE NOT RECRUITING Phase 2

Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia

NCT04994808

ACTIVE NOT RECRUITING Phase 1

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

NCT05359211

ACTIVE NOT RECRUITING Phase 3

An Innovative Conversational Agent (Quitbot) for Smoking Cessation

NCT04308759

ACTIVE NOT RECRUITING NA

Testing Counseling and Mobile Health Interventions to Improve Physical Activity and Diet Quality in Survivors of Childhood Cancer

NCT05075759

ACTIVE NOT RECRUITING Phase 2

Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes

NCT03399773

ACTIVE NOT RECRUITING Phase 3

Quit2Heal Smartphone App in Helping Cancer Patients Quit Smoking

NCT04409236

ACTIVE NOT RECRUITING NA

An AHEI Dietary Intervention to Reduce Pain in Women With Endometriosis

NCT04259788

ACTIVE NOT RECRUITING Phase 2

Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant

NCT04572815

ACTIVE NOT RECRUITING Phase 3

Telephone Delivered Weight Loss, Nutrition, Exercise WeLNES Study

NCT04447313

ACTIVE NOT RECRUITING Phase 2

Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis

NCT04384692

ACTIVE NOT RECRUITING Phase 2

Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease

NCT04198922

ACTIVE NOT RECRUITING Phase 2

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients

NCT04195945

ACTIVE NOT RECRUITING NA

Survivorship Care Plans and Telehealth Education for the Improvement of Access to Cancer Survivorship, the IMPACT Study

NCT04081779

ACTIVE NOT RECRUITING Phase 1

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

NCT03277729

ACTIVE NOT RECRUITING Phase 2

JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

NCT02251821

ACTIVE NOT RECRUITING

Chronic GVHD Response Measures Validation

NCT01902576

ACTIVE NOT RECRUITING Phase 2

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

NCT00716066

ACTIVE NOT RECRUITING

Improving Outcomes Assessment in Chronic GVHD

NCT00637689

COMPLETED NA

Attention Bias Modification for the Improvement of Anxiety in Adolescent and Young Adult Cancer Survivors

NCT06682039

COMPLETED NA

An Escape Room Intervention to Help Improve Breast Cancer Patients' Ability to Navigate Online Access to Nutrition Information

NCT06193070

COMPLETED NA

Educational Intervention for the Promotion of Knowledge and Preventive Health Behaviors Related to Personal Air Pollution Exposure, The Air Study

NCT04922697

COMPLETED

Tailoring Shared Decision Making for Lung Cancer Screening in Persons Living With HIV

NCT04682301

COMPLETED Phase 1

Website Smoking Cessation Intervention for the Promotion of Smoking Cessation in Low-Income Veterans

NCT04502524

COMPLETED NA

Clinical Outcomes for Offering Genetic Testing in a Tiered Approach

NCT04902144

COMPLETED NA

Effects of Alternative Healthy Eating Index-Based Diet on Inflammatory Markers and Breast Density in Healthy Participants

NCT04062955

COMPLETED NA

Yeego! Healthy Eating & Gardening School-Based Randomized Controlled Trial

NCT03778021

COMPLETED NA

Positive Psychology Intervention to Improve Quality of Life in Stem Cell Transplant Survivors and Their Caregivers

NCT03525106

COMPLETED NA

Smoking Cessation Smartphone App for Cancer Patients (Quit2Heal Study)

NCT03600038

COMPLETED Phase 2

MMF for HIV Reservoir Reduction

NCT03262441

COMPLETED Phase 1

Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma

NCT03338972

COMPLETED Phase 1

Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS

NCT02921061

COMPLETED NA

Computerized Cognitive Retraining in Improving Cognitive Function in Breast Cancer Survivors

NCT02662335

COMPLETED NA

The Impact of Low-fat and Full-fat Dairy Consumption on Glucose Homeostasis (DAIRY Study)

NCT02663544

COMPLETED Phase 2

Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease

NCT02491359

COMPLETED Phase 1

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

NCT02044796

COMPLETED Phase 2

CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT01881867

COMPLETED Phase 2

Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma

NCT01807182

COMPLETED Phase 2

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant

NCT01812252

COMPLETED NA

Supportive Care for Patients With Hematological Malignancies Undergoing Hematopoietic Cell Transplant

NCT01758484

COMPLETED NA

Innovative Smartphone Application of a New Behavioral Method to Quit Smoking: Pilot Trial (Smart Quit)

NCT01812070

COMPLETED

Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life

NCT01930981

COMPLETED NA

Glucosamine and Chondroitin Effects

NCT01682694

COMPLETED Phase 1

90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

NCT01503242

COMPLETED NA

Vitamin D and Adipose Tissue Inflammation

NCT01477034

COMPLETED Phase 2

Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure

NCT01335932

COMPLETED

Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation

NCT01206309

COMPLETED NA

Meals and Grazing Study

NCT02548026

COMPLETED NA

MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation

NCT01178892

COMPLETED Phase 1

Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS

NCT01141725

COMPLETED Phase 1

Effects of Sulforaphane on Normal Prostate Tissue

NCT00946309

COMPLETED

Malaria Clinical Trials Center General Screening

NCT02119312

What the Pipeline for Fred Hutchinson Cancer Center Shows

According to the ClinicalTrials.gov registry, Fred Hutchinson Cancer Center is linked to 319 US clinical trials across every stage of research activity. Of those, 224 studies are currently recruiting — about 70% of the sponsor's indexed portfolio — and 75 are already marked complete, representing roughly 24% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Fred Hutchinson Cancer Center reports 8 late-stage studies (Phase 3 and Phase 4 combined) and 175 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Fred Hutchinson Cancer Center is Acute Myeloid Leukemia with 10 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial